Former Novartis man becomes GSK’s new medical director
pharmafile | May 8, 2012 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | GSK, James Shannon, Novartis
James Shannon has been named GSK’s chief medical officer, and will report to R&D chairman Moncef Slaoui.
He will be based in London and be accountable for medical governance and patient safety for all of GSK: pharmaceuticals, consumer healthcare, vaccines and the global businesses.
Shannon, who is trained in cardiology, has more than 20 years’ experience at senior levels of the pharma industry.
Most recently, he was global head of drug development for Novartis. Since leaving the firm in 2008, he has served on the boards of a number of companies.
Shannon said: “One reason I wanted to come to GSK is that the company’s values so closely match my own.
“The commitment to quality, transparency and focus on the patient are certainly values that I can fully support and demonstrate as CMO to the benefit of patients and healthcare professionals around the world.”
Related Content

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis
GSK’s Exdensur (depemokimab), a twice-yearly biological medicine, has received approval from the UK Medicines and …

Novartis receives SMC approval for early breast cancer treatment
Novartis has announced that its treatment for early breast cancer, Kisqali (ribociclib), has received approval …

Novartis candidate for Sjögren’s disease presents positive results
Novartis has reported positive results from two phase 3 clinical trials – NEPTUNUS-1 and NEPTUNUS-2 …





